Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant

Patients with kidney disease taking Ionis Pharmaceuticals and Bayer’s anti-thrombotic therapy did not experience an increase in major bleeding events as compared to those taking placebo, meaning patients may someday have a new anticoagulant option that does not come with a risk of bleeding.